Loading organizations...
OXOS Medical is a technology company.
OXOS Medical builds portable X-ray solutions that deliver high-quality diagnostic images with significantly reduced radiation exposure. Their core product, MC2, offers a modular, user-friendly system designed for point-of-care diagnostics. These devices feature optimized X-ray alignment capabilities and a no-fire positioning system, ensuring both excellent image clarity and enhanced safety for patients and providers by minimizing radiation.
The company was founded in June 2016 as Micro C, LLC, by Evan M. Ruff, who serves as CEO, and Gregory P. Kolovich, MD, the Chief Medical Officer. Dr. Kolovich, a reconstructive hand surgeon with a background at Harvard Medical School, conceived the initial idea from a personal frustration with the limitations of traditional imaging processes, leading to the development of the portable Micro C device from what began as a simple sketch.
OXOS Medical's portable X-ray devices are utilized across prominent medical facilities and practices, serving diverse specialties including orthopedics, pediatrics, and sports medicine. The company’s vision is to enable widespread access to radiographic diagnostics at the point of need, thereby expanding availability and fundamentally transforming how healthcare services are delivered globally.
OXOS Medical has raised $23.0M across 1 funding round.
OXOS Medical has raised $23.0M in total across 1 funding round.
OXOS Medical has raised $23.0M in total across 1 funding round.
OXOS Medical's investors include Intel Capital, Gregg Hill, SoftBank Investment Advisers, Ed Baker.
# OXOS Medical: Transforming Portable X-ray Imaging
OXOS Medical develops portable, AI-enabled X-ray devices that reduce radiation exposure by 80% while maintaining image quality, targeting underserved healthcare markets globally.[1][3] Founded in June 2021, the Atlanta-based company addresses a critical healthcare access gap: approximately 80% of the world's population lacks access to diagnostic imaging, despite X-ray being the primary imaging modality used in over 70% of health interventions.[3][5]
The company's core mission is to expand access to radiographic diagnostics at the point of need—placing safe, powerful, and simple X-ray technology in the hands of urgent care centers, sports teams, home care providers, and international mission operations.[3][5] OXOS serves orthopedic and radiographic professionals across diverse care scenarios, from traditional medical settings to non-medical applications. The company has achieved FDA 510(k) clearance for its handheld X-ray system and has secured significant funding, including a $23 million investment round, to accelerate global product availability and innovation.[6]
OXOS Medical was founded in June 2021 by Evan Ruff, who serves as CEO and co-founder.[3][5][8] The company emerged from a recognition that portable X-ray technology could fundamentally reshape healthcare delivery in resource-constrained environments. Ruff's vision centers on democratizing access to diagnostic imaging—a technology that remains concentrated in developed healthcare systems despite its critical importance to patient outcomes worldwide.
The company's early product, the Micro C Medical Imaging System, achieved FDA clearance and demonstrated market traction, validating the demand for portable, low-radiation X-ray solutions.[6] This success led to the development of the MC2, the company's core product offering as of August 2024, which incorporates user feedback and enhanced capabilities including four distinct imaging modes: Radiography, Dynamic Digital Radiography (DDR), Fluoroscopy, and Photography.[2]
OXOS operates at the intersection of three powerful trends: AI-driven medical device innovation, point-of-care diagnostics, and global health equity. The company addresses a market failure where diagnostic imaging—essential infrastructure for modern medicine—remains inaccessible to the majority of the world's population due to cost, size, and infrastructure requirements of traditional equipment.
The timing is particularly significant. Healthcare systems worldwide are shifting toward distributed care models, accelerated by pandemic-era telemedicine adoption and growing recognition that centralized diagnostic facilities create bottlenecks in patient care. Simultaneously, AI maturation enables real-time image optimization and interpretation at the edge, reducing dependence on expert radiologists in resource-limited settings. OXOS' low-radiation profile also aligns with growing clinical awareness of cumulative radiation risks, particularly important in orthopedic and sports medicine where serial imaging is common.
The company's cloud-connected architecture positions it within the broader digital health ecosystem, enabling future integration with AI-powered diagnostic algorithms and electronic health records. By making X-ray technology accessible in non-traditional settings—sports sidelines, urgent care clinics, home care—OXOS is reshaping where and how diagnostic imaging occurs, potentially influencing clinical workflows across the healthcare industry.
OXOS Medical is well-positioned to capture significant market share in the rapidly expanding point-of-care diagnostics segment. The company's $23 million funding round signals investor confidence in both the technology and the massive addressable market of underserved regions and emerging care settings.
Looking ahead, OXOS' trajectory will likely be shaped by three factors: regulatory expansion (securing clearances in additional markets and imaging modalities), AI algorithm development (building or partnering on diagnostic interpretation tools), and market penetration in high-growth segments like urgent care and international healthcare. The company's ability to scale manufacturing while maintaining quality and cost advantages will determine whether it becomes the standard for portable X-ray imaging globally.
As healthcare systems increasingly prioritize accessibility, safety, and efficiency, OXOS' combination of low-radiation technology, portability, and AI intelligence positions it as a potential category leader—not just in portable X-ray devices, but in reshaping how diagnostic imaging is delivered to the 80% of the world currently without access.
OXOS Medical has raised $23.0M across 1 funding round. Most recently, it raised $23.0M Series A in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $23.0M Series A | Intel Capital, Gregg Hill | SoftBank Investment Advisers, Ed Baker |